Investment aims to improve infection prevention

A University of Manchester spin-out behind a medical device designed to detect life-threatening infections will begin its first clinical trial following a £1.4 million investment boost. Through its iPad mini-sized device, MicroBioSensor aims to help people with kidney failure undergoing peritoneal dialysis.

Based at The University of Manchester’s Innovation Centre (UMIC), MicroBioSensor recently secured the finance from the Northern Powerhouse Investment Fund (NPIF) and Catapult Ventures. MicroBioSensor CEO Dr Gordon Barker (pictured) said: “2018 is going to be a very important year for our 11-strong team as we look to run our first clinical trial which will last through to the second quarter of 2019. Essentially, this is all about detecting potentially life-threatening infections early, to improve treatment outcomes.”

Dr Barker said that of the 50,000 to 60,000 people in the UK on renal replacement therapy, less than 10% are on peritoneal dialysis. “One of the reasons for this is because people are worried about infection in the peritoneal cavity. Our device plugs into the equipment that dialysis patients use every day and detects emerging infections in this space, which potentially means keeping people on peritoneal dialysis for longer. If the clinical trial goes well, we’ll be able to start selling the medical device for use in hospitals and clinics. The idea is that eventually it will be used at home by patients, as the technology is so simple that a non-specialist can use it with confidence.


Other news

Upcoming Events

Focus 2019

SEC Glasgow
1-3 May 2019

Respiratory Microbiology - A Day of Inspiration

Royal Air Force Museum, Hendon
16 May 2019

Clinical and Laboratory Haemostasis 2019

The Atrium Conference Centre, Sheffield Hallam University
5-6 June 2019

The Oxford Haematology in Obstetrics Postgraduate Course

St Edmund Hall, Queen's Lane, Oxford OX1 4AR
9-11 September 2019

IBMS Biomedical Science Congress

ICC, Birmingham
22-25 September 2019

Latest Issue

Pathology In Practice

Pathology In Practice

Apr 2019

Reducing exposure to antimicrobial agents

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.